FDA Approves ABRAXANE(R) for Pancreatic Cancer, Could Nuvilex's Treatment Be Next
September 09, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Sep 9, 2013) - After presenting the results of its large scale Phase III clinical trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of...
Nuvilex Investors Watch as Incyte Shares Rise Sharply on Pancreatic Cancer Trials Data
August 28, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 28, 2013) - As Nuvilex, Inc. (OTCQB: NVLX) continues to methodically build its brand as a biotechnology firm ahead of its future Phase III clinical trials for the...
Nuvilex Remains Under Fire While Investors Hold
August 27, 2013 10:10 ET
|
Nuvilex, Inc.
SAN DIEGO, CA--(Marketwired - Aug 27, 2013) - The OTC Journal, the longest running electronic newsletter focused on the small cap and microcap sectors, suggests investors consider the agenda when...
Drug Makers Could Soon Turn Away From Eli Lilly's Gemzar and Toward Nuvilex's Cell Encapsulation
August 22, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Aug 22, 2013) - While Eli Lilly's cancer fighting drug Gemzar (gemcitabine) has been on the market since the late 1990s, its success with cancer duly noted, other big...
Nuvilex, Inc. Strengthens Its Hand in the Cancer Arena With Purchase of Assets
July 30, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jul 30, 2013) - Nuvilex, Inc. (OTCQB: NVLX) became a much more valuable company in July when it closed a deal it was fully prepared to pay a great deal more money for,...
Nuvilex, Inc. Moves Closer to Head to Head With Eli Lilly in Phase III Clinical Trials
July 25, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jul 25, 2013) - Nuvilex, Inc. (OTCQB: NVLX) is currently preparing the way to challenge Eli Lilly's blockbuster cancer drug, Gemzar, and doing so with the knowledge...
Nuvilex, Inc. Will Enter Phase III Trials With Advantages Using Cell Encapsulation
July 09, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jul 9, 2013) - When Nuvilex, Inc. (OTCQB: NVLX) enters its pivotal Phase III clinical trial using its cell encapsulation technology combined with the anti-cancer drug...
Nuvilex, Inc. a Biotech Developing Treatments for Healthcare's Hard Targets
June 26, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 26, 2013) - Nuvilex, Inc. (OTCQB: NVLX) executives aren't daunted by the statistics. As a matter of fact, they're aware the research they do is directed...
Nuvilex, Inc.'s Cell Encapsulation Could Play Role in Multimodality Treatment of Cancer Patients
June 06, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 6, 2013) - Nuvilex, Inc. (OTCQB: NVLX) has a technology in its cell encapsulation process that will very likely play some role in the future of oncology. How...
Nuvilex, Inc. Could Become Significant Player in the Oncology Arena With Successful Phase III Trials
May 22, 2013 08:30 ET
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 22, 2013) - Nuvilex, Inc. (OTCQB: NVLX) is a diamond in the rough in the truest sense. Currently shares of the Silver Spring, Maryland, biotechnology firm can...